the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email .

Developmental Therapeutics (Phase I) Cancer Clinical Trials
Interventional only

Study No PI Title
IRB16-1506 Sweis, Randy An Open Label, Non-Randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1163877 in Subjects with Refractory, Locally Advanced or Metastatic Solid Tumors Details
IRB17-1038 Luke, Jason A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms Details
IRB17-0762 Luke, Jason A Phase 1 Open-label, Multicenter Study of MK-2118Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab for Patients with Advanced/Metastatic Solid Tumors or Lymphomas Details
IRB17-0603 Luke, Jason A Phase Ib, open label, multicenter study of the safety and efficacy of MIW815 (ADU-S100) administered by intratumoral injection with PDR001 to patients with advanced/metastatic solid tumors or lymphomas Details
IRB17-0681 Sharma, Manish A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009) Details
IRB16-1743 Ratain, Mark An Open Label Phase I, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies Details
IRB16-1735 Luke, Jason A Multicenter, Phase I, Open-Label, Dose-Escalation Study of ABBV-181, a Monoclonal Antibody Targeting PD1, in Subjects with Advanced Solid Tumors Details
IRB16-1071 Luke, Jason A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors Details
IRB16-0538 Luke, Jason A Multi-Center, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies Whose Disease has Progressed on PD-1 or PD-L1 Immune Checkpoint Inhibitors Details
IRB15-1561 Luke, Jason A Phase Ia/Ib Study of Cabiralizumab in Combination with Nivolumab in Patients with Selected Advanced Cancers Details
IRB16-0297 Sharma, Manish A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of Selumetinib (AZD6244 Hyd sulfate) in Combination with MEDI4736 in Patients With Advanced Solid Tumours Details
IRB16-0046 Fleming, Gini Phase I/II Study of CORT125134 in Combination with Nab-paclitaxel in Patients with Solid Tumors Details
IRB16-0257 Luke, Jason A Two Part, Phase I, Multicenter, Open-Label Study of TRX518 in Adults with Advanced Solid Tumors Part A: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part B: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose Details
CIRB15-1357 Sharma, Manish EAY131: Molecular Analysis for Therapy Choice (MATCH) Details
IRB15-1807 Luke, Jason A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients with Advanced/Metastatic Solid Tumors or Lymphomas Details
IRB15-1767 Luke, Jason A Phase I/Ib, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers Details
IRB15-1002 Sharma, Manish An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin’s Lymphoma and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer Details
IRB15-1024 Luke, Jason A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors Details
IRB15-1130 Luke, Jason Phase I study of PD1 blockade by pembrolizumab with stereotactic body radiotherapy in advanced solid tumors Details
IRB15-0835 Luke, Jason A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma Details
IRB15-0396 Fleming, Gini A Phase Ib Study of The Safety and Pharmacology of MPDL3280A Administered with Bevacizumab and/or Chemotherapy in Patients with Advanced Solid Tumors Details
IRB14-1428 Gajewski, Thomas A Phase 1, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies Details
IRB14-0704 Gajewski, Thomas A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors Details
IRB14-0987 Sharma, Manish A First-in-Human Phase 1, Dose Escalation, Safety and Pharmacokinetic Study of PF-06647020 in Adult Patients with Advanced Solid Tumors Details
IRB14-0862 Fleming, Gini My Pathway - An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents Details
IRB13-0936 Gajewski, Thomas A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors Details
12-1667 Gajewski, Thomas A Phase I/II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Details
13-0002 Sharma, Manish A Registry for Serial Imaging and Plasma Assessment in Advanced Solid Tumor Patients
10-487-A O'Donnell, Peter The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing Details

Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .